BCAL Diagnostics Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Shane Ryan

Directeur général

AU$667.0k

Rémunération totale

Pourcentage du salaire du PDG	41.1%
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	3.6yrs

Mises à jour récentes de la gestion

Recent updates

Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?

Aug 08

Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In Growth

Apr 07

Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn Situation

Dec 23

Analyse de la rémunération des PDG

Comment la rémunération de Shane Ryan a-t-elle évolué par rapport aux bénéfices de BCAL Diagnostics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	AU$667k	AU$274k	-AU$6m

Rémunération vs marché: La rémunération totale de Shane ($USD 433.10K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 295.69K ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Shane avec les performances de l'entreprise.

PDG

Shane Ryan

less than a year

Titularisation

AU$667,016

Compensation

Mr. Shane Ryan, MBA is Chief Executive Officer of BCAL Diagnostics Limited from 2024. He joined the BCAL Diagnostics Limited on September 21, 2023. He was Chief Operating Officer of BCAL Diagnostics Limite...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jayne Shaw	Co-Founder & Executive Chairman	14.8yrs	AU$180.00k	8.33% A$ 3.3m
Ronald Phillips	Co-Founder & Non-Executive Director	14.8yrs	AU$54.67k	7.08% A$ 2.8m
John Hurrell	Independent Non-Executive Director & Consultant	less than a year	AU$658.25k	1.54% A$ 606.4k
Mark Burrows	Independent Non-Executive Director	3.3yrs	AU$54.67k	0.40% A$ 159.5k
David Darling	Non-Executive Director	less than a year	AU$28.99k	0.010% A$ 3.9k
Jonathan Alfred Trollip	Independent Non-Executive Director	3.9yrs	AU$59.00k	1.48% A$ 583.4k

3.6yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de BDX sont considérés comme expérimentés (ancienneté moyenne 3.6 ans).

BCAL Diagnostics Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2024

Less than half of directors are independent

Co-Founder & Non-Executive Director exercised options to buy AU$212k worth of stock.

BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

Recent updates

BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2024

Full year 2024 earnings: EPS misses analyst expectations

New major risk - Shareholder dilution

BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 10.5 million.

New minor risk - Share price stability

Less than half of directors are independent

First half 2024 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in 1H 2023)

Co-Founder & Non-Executive Director exercised options to buy AU$212k worth of stock.

BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.

BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023

Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

New minor risk - Shareholder dilution

Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)

New minor risk - Financial data availability

Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

New major risk - Market cap size

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.006 loss in 1H 2022)

High number of new and inexperienced directors

BCAL Diagnostics Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In Growth

High number of new and inexperienced directors

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Bcal Diagnostics Limited Provides Additional Information on Recent Analysis to Distinguish Between Blood Samples of Breast Cancer Patients and Normal Control Samples

Bcal Diagnostics Limited Announces Recent Analysis Significantly Improves Commercial Prospects

Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn Situation

Full year 2021 earnings released: AU$0.011 loss per share (vs AU$0.006 loss in FY 2020)

BCAL Diagnostics Limited Commences Collecting Samples for the First Stage of Its Australian Clinical Program

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi